Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perseus ProteomicsTSE:4882 +2.56%56 Forward Dividend Yield % is 0.00% as of Jul. 16, 2026. GuruFocus rates TSE:4882 with a GF Score™ of 56/100 and a GF Value™ of 円439.72 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 512 Drug Manufacturers companies, Perseus Proteomics ranks worse than 195312.3% on this metric.
As of today (2026-07-16), the Forward Annual Dividend Yield of Perseus Proteomics is 0.00%.
As of today (2026-07-16), the Trailing Annual Dividend Yield of Perseus Proteomics is 0.00%.
TSE:4882's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.005 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Perseus Proteomics Forward Dividend Yield % Related Terms
TSE:4882 vs LLY, JNJ, ABBV: Forward Dividend Yield % Comparison
For the Drug Manufacturers - General subindustry, Perseus Proteomics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Perseus Proteomics (TSE:4882) has a Forward Dividend Yield % of 0.00% as of Jul. 16, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Perseus Proteomics and its competitors. According to the industry distribution chart, Perseus Proteomics ranks #999999 out of 512 companies in the Drug Manufacturers industry.
Is Perseus Proteomics' Forward Dividend Yield % too high?
Perseus Proteomics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Perseus Proteomics ranks #999999 out of 512 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' Forward Dividend Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #999999 out of 512 companies for Forward Dividend Yield %. This places Perseus Proteomics in the lower half of its industry. The industry median Forward Dividend Yield % is 2.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.01, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Perseus Proteomics and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.72, compared to a current price of 円160.00 — trading 63.6% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current Forward Dividend Yield % is 0.00% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円160.00 is trading 63.6% below its estimated GF Value™ of 円439.72.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
Forward Dividend Yield %: 0.00%
GF Value™: 円439.72 vs. price of 円160.00 (63.6% below fair value)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score
Get the complete analysis for TSE:4882
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
